Symbiotec Pharmalab Adopts Code of Fair Disclosure for UPSI Under SEBI Regulations
Symbiotec Pharmalab Ltd 路 Others (Uncategorized) 路 03 Sept 2026, 7:17 pm
Symbiotec Pharmalab Adopts Code of Fair Disclosure for UPSI Under SEBI Regulations On 3rd Sep'26, Symbiotec Pharmalab filed its Code of Practices for Fair Disclosure of Unpublished Price Sensitive Information (UPSI), effective 15th Dec'25. Mandated by SEBI, the policy enforces prompt, universal dissemination of price-sensitive data and strict confidentiality on a need-to-know basis for legitimate business purposes. To ensure strict compliance and transparency, the Board appointed a Chief Investor Relations Officer (CIRO) reporting directly to the CFO. The CIRO will exclusively oversee UPSI disclosure, verify market rumors, and manage all official communications with stock exchanges and media.
Original exchange filing (PDF)
More announcements from Symbiotec Pharmalab Ltd
- Intimation regarding change in Corporate Identification Number (CIN) and Listing Status of the Company. 路 17 Nov 2026
- Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended 路 12 Nov 2026
- Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time .... 路 12 Nov 2026
- Pursuant to Part A of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audio recording of Conference Call for Analysts and Investors held on November .... 路 06 Nov 2026
- Symbiotec Signs 10 Year take or Pay Agreement to Manufacture Fermentation based alternative protein for EU Innovator 路 06 Nov 2026
- The Monitoring Agency report issued by the CARE Edge Ratings, Monitoring Agency, appointed by the Company for the utilisation and application of funds raised through the IPO of the Company .... 路 06 Nov 2026
- The Investor release being issued by the company, for the quarter and half year ended September 30, 2026 路 06 Nov 2026
- Pursuant to regulations 30 of the SEBI Listing Regulations, Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026. 路 06 Nov 2026
